Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University Study.
Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University Study.
复制标题
DOI：
--
复制
发表时间：
1987-07
期刊：
影响因子：
--
通讯作者：
M. al-Sarraf;B. Metch;J. Kish;J. Ensley;J. Rinehart;D. Schuller;C. Coltman
中科院分区：
文献类型：
--
作者：
M. al-Sarraf;B. Metch;J. Kish;J. Ensley;J. Rinehart;D. Schuller;C. Coltman
顺铂联合用药对头颈部表皮样癌患者很有效。由于剂量限制性毒性的发生率和静脉补液和甘露醇利尿需要住院治疗，因此一直在密集寻找具有较少此类毒性的活性类似物。在韦恩州立大学和西南肿瘤学小组的有限机构研究中，在复发性头颈癌患者中进行了卡铂（CBDCA）和异丙铂（CHIP）的临床试验。64例患者入组，63例接受评价，29例接受CBDCA，34例接受CHIP治疗。根据重要的预后因素对这些患者进行分层。CBDCA的应答率为24%（29例患者中有7例应答; 3例完全应答和4例部分应答），CHIP的应答率为12%（34例患者中有4例应答; 1例完全应答和3例部分应答）。这两种药物的给药均在门诊基础上进行，既往未进行水合或甘露醇利尿。主要的副作用是骨髓抑制，这是可逆的，但累积和剂量限制。与顺铂的毒性发生率相比，发生的呕吐不太严重，未发生显著的肾脏或听力损失。得出的结论是，在头颈癌患者中进一步评价这些药物与其他活性药物的疗效是必要的。
Cisplatin combinations are active in patients with epidermoid cancer of the head and neck. Because of the incidence of dose-limiting toxicity and the need for hospitalization for iv hydration and mannitol diuresis, the search for active analog(s) with less of such toxicity has been intensive. In a limited institution study of Wayne State University and the Southwest Oncology Group, a clinical trial of carboplatin (CBDCA) and iproplatin (CHIP) in patients with recurrent head and neck cancer was carried out. Sixty-four patients were entered and 63 were evaluated, 29 receiving CBDCA and 34 receiving CHIP therapy. These patients were stratified according to important prognostic factors. The response rate to CBDCA was 24% (seven responses among 29 patients; three complete responses and four partial responses), and to CHIP was 12% (four responses among 34 patients; one complete response and three partial responses). Both drugs were administered without prior hydration or mannitol diuresis on an outpatient basis. The major side effect was myelosuppression, which was reversible but cumulative and dose-limiting. Less severe vomiting occurred as compared to the incidence of this toxicity with cisplatin and no significant renal or hearing loss occurred. It was concluded that further evaluation of these agents with other active drug(s) in patients with head and neck cancer is warranted.